Company intelligence / Profile preview
Qihan Biotech
Hangzhou, Zhejiang, Chinaqihanbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has received NMPA approval for its IND application for QN-019a, a multi-locus gene-editing cell therapy product to treat CD19-positive B-Cell Lymphoma. Several programs are in Phase 1 clinical trials, including CD33 CAR-NK cell therapy for relapsing and refractory acute myeloid leukemia.
- Therapeutic areas
- OncologyNephrologyHematology
- Modalities
- Cell therapyGene editingOrgan transplantationCAR-NK cell therapyiNKT cell therapyNatural Killer Cell Therapies
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Zhejiang University
Beyond the preview
Go deeper on Qihan Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qihan Biotech.